Focalin Capsule, Extended Release
NDC Package 0078-0608-05
Package Information
Focalin (dexmethylphenidate hydrochloride) capsules is focalin XR is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) [see Clinical Studies (14)].Limitations of UseThe use of Focalin XR is not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure and a higher incidence of adverse reactions (e.g., weight loss) than patients 6 years and older at the same dosage [see Warnings and Precautions (5.7), Use in Specific Populations (8.4)]. This formulation utilizes a capsule, extended release delivery system. Marketed by Novartis Pharmaceuticals Corporation, this product is identified by NDC 0078-0608 and is authorized under FDA application NDA021802.
Identification & Billing
- RxCUI: 1006608 - dexmethylphenidate HCl 40 MG 24HR Extended Release Oral Capsule
- RxCUI: 1006608 - 24 HR dexmethylphenidate hydrochloride 40 MG Extended Release Oral Capsule
- RxCUI: 1006608 - dexmethylphenidate hydrochloride 40 MG 24 HR Extended Release Oral Capsule
- RxCUI: 1006610 - Focalin XR 40 MG 24HR Extended Release Oral Capsule
- RxCUI: 1006610 - 24 HR dexmethylphenidate hydrochloride 40 MG Extended Release Oral Capsule [Focalin]
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 0078 - Novartis Pharmaceuticals Corporation
- 0078-0608 - Focalin
- 0078-0608-05 - 100 CAPSULE, EXTENDED RELEASE in 1 BOTTLE
- 0078-0608 - Focalin
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 0078-0608-05 identifies a specific commercial package of 100 capsule, extended release in 1 bottle of Focalin XR, a human prescription drug labeled by Novartis Pharmaceuticals Corporation. This capsule, extended release is formulated for oral use and contains dexmethylphenidate hydrochloride as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Novartis Pharmaceuticals Corporation on May 31, 2005.
How is this Novartis Pharmaceuticals Corporation product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 00078060805. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 100 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.